Literature DB >> 17938033

Primary cutaneous anaplastic large cell lymphoma with fatal leukemic outcome in association with CLA and CCR4-negative conversion.

Yoshiki Tokura1, Kazunari Sugita, Hiroaki Yagi, Takatoshi Shimauchi, Kenji Kabashima, Masahiro Takigawa.   

Abstract

A 70-year-old Japanese male presented with a 1-year history of skin tumors, which were diagnosed as primary cutaneous anaplastic large cell lymphoma (ALCL) because of the CD3(low+), CD4(+), CD25(+), CD30(+), CD45RO(+), CD71(+), HLA-DR(+), CD8(-), CD56(-), and NPM/ALK(-) phenotype and monoclonal T-cell receptor-rearranged property of tumor cells as well as the absence of systemic involvement. At this time, the tumor cell was positive for cutaneous lymphocyte-associated antigen (CLA) and TH(2) chemokine receptor CCR4. The eruption had repeatedly appeared and spontaneously regressed or regressed by virtue of several therapeutic modalities, including radiotherapy, interferon-alpha and chemotherapy, until the tumor cell invaded the gastric mucosa and spread to the peripheral blood 5 years later. Upon progression to the fatal leukemic change, the skin lesions inversely disappeared. Flow cytometric monitoring of the phenotype of peripheral blood and skin-infiltrating lymphocytes disclosed that the expression of CLA and CCR4 on the tumor cells was converted from positive to negative in association with the leukemic change. The altered expression of skin-homing receptors might change its clinical behavior.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17938033     DOI: 10.1016/j.jaad.2006.08.053

Source DB:  PubMed          Journal:  J Am Acad Dermatol        ISSN: 0190-9622            Impact factor:   11.527


  2 in total

1.  Differential diagnosis and treatment of primary, cutaneous, anaplastic large cell lymphoma: not always an easy task.

Authors:  Michael D Diamantidis; Athanasios Papadopoulos; Georgia Kaiafa; George Ntaios; Georgia Karayannopoulou; Ioannis Kostopoulos; Fotios Girtovitis; Zoi Saouli; Zisis Kontoninas; Ioannis D Raptis; Christos Savopoulos; Apostolos Hatzitolios
Journal:  Int J Hematol       Date:  2009-06-23       Impact factor: 2.490

2.  Humanization of an anti-CCR4 antibody that kills cutaneous T-cell lymphoma cells and abrogates suppression by T-regulatory cells.

Authors:  De-Kuan Chang; Jianhua Sui; Shusheng Geng; Asli Muvaffak; Mei Bai; Robert C Fuhlbrigge; Agnes Lo; Anuradha Yammanuru; Luke Hubbard; Jared Sheehan; James J Campbell; Quan Zhu; Thomas S Kupper; Wayne A Marasco
Journal:  Mol Cancer Ther       Date:  2012-08-06       Impact factor: 6.261

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.